G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.27 USD -3.64% Market Closed
Market Cap: 482.3m USD
Have any thoughts about
GH Research PLC?
Write Note

GH Research PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GH Research PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Cash from Operating Activities
-$33.3m
CAGR 3-Years
-366%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Cash from Operating Activities
$259m
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Cash from Operating Activities
$1.2B
CAGR 3-Years
14%
CAGR 5-Years
5%
CAGR 10-Years
13%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Cash from Operating Activities
-$82.8m
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-22%
Cosmo Pharmaceuticals NV
SIX:COPN
Cash from Operating Activities
€117.3m
CAGR 3-Years
82%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Ovoca Bio PLC
LSE:OVB
Cash from Operating Activities
€404k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GH Research PLC
Glance View

Market Cap
482.3m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
4.27 USD
Overvaluation 54%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Cash from Operating Activities?
Cash from Operating Activities
-33.3m USD

Based on the financial report for Dec 31, 2023, GH Research PLC's Cash from Operating Activities amounts to -33.3m USD.

What is GH Research PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-366%

Over the last year, the Cash from Operating Activities growth was -27%. The average annual Cash from Operating Activities growth rates for GH Research PLC have been -366% over the past three years .

Back to Top